Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.72 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.59 |
| ▸ | FLT3 | P36888 | 10/20 | 0.59 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918611 | 0.90 | CHEK1 (0.72) | CHEK1PRKCQFLT3PTK2SYK | |
| SCHEMBL1916305 | 0.90 | CHEK1 (0.72) | CHEK1PRKCQFLT3PTK2SYK | |
| SCHEMBL1917067 | 0.88 | CHEK1 (0.65) | CHEK1PRKCQFLT3PTK2SYK | |
| SCHEMBL1916416 | 0.85 | CHEK1 (0.69) | CHEK1PRKCQFLT3 | |
| SCHEMBL1916646 | 0.85 | PRKCQ (0.78) | CHEK1PRKCQFLT3PTK2 | |
| SCHEMBL28387322 | 0.84 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL1916707 | 0.77 | JAK3 (0.57) | CHEK1MAP4K1PTK2 | |
| SCHEMBL1937645 | 0.76 | PRKCQ (0.65) | CHEK1PRKCQFLT3PTK2 | |
| SCHEMBL1917777 | 0.75 | PRKCQ (0.71) | CHEK1PRKCQFLT3PTK2 | |
| SCHEMBL1917236 | 0.75 | PRKCQ (0.81) | CHEK1PRKCQFLT3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420630-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2090571-B1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-16 | — | — | EP | disclosed |
| EP-2332924-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | disclosed |
| EP-2090571-A1 | Pyrimidine derivates, medicaments comprising them, their use and process of their preparation | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2009-08-19 | — | — | EP | disclosed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | CHEK1 409/4885PRKCQ 3224/4885FLT3 278/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | CHEK1 409/4885PRKCQ 3224/4885FLT3 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.